Concept of cancer therapy

Cancer Treatment at Saisei

Begin your journey to wellness with us and discover your body’s inherent vitality!

What is Cancer?

Cancer involves uncontrolled cell growth and potential spread throughout the body. Normally, cells grow, divide, and replace in a regulated manner, but when this process fails, abnormal cells and possibly tumors develop. These tumors may be malignant, spreading and potentially forming new tumors elsewhere, or benign non-cancerous, staying localized without invading nearby tissues. Malignant tumors can metastasize and may recur after removal, whereas benign tumors generally do not, though they can still be dangerous if in critical areas like the brain.

Immunotherapy for Cancer Treatment

Immunotherapy boosts the immune system to fight cancer, using substances from living organisms. Normally, the immune system, which includes white blood cells and lymphatic organs, detects and destroys abnormal cells to prevent cancer. Immunotherapy aids this natural defense by making it more effective, especially by enhancing the action of tumor-infiltrating lymphocytes (TILs) within tumors.

Cancer Treatment approaches at SAISEI

Our clinic combines established and innovative immunotherapy techniques, including unique treatments like GcMAF therapy, developed through global research partnerships. We offer a range of scientifically-backed methods, tailored to each patient, that have proven effective alone or in combination. GcMAF therapy, a standout in our offerings, is gaining international acclaim based on extensive research and clinical trials. We provide access to a wealth of scientific literature on our website, highlighting our commitment to advancing medical knowledge and offering globally recognized treatments.

Concept of Cancer therapy at SAISEI

Destruction of local cancer tissue

・Sonophotodynamic Therapy  (SDT)

・High-Intensity Focused Ultrasound  (HIFU)

・Saisei Tumor Treating Fields (TTF) Therapy


・Serum GcMAF

・Autologous GcMAF

・Oral MAF

・Hyper T/NK cell therapy

・Coley’s vaccine

・Autologous cancer vaccine

・Dendritic cell therapy

New Cancer Therapy at Saisei Mirai

  • P53 tumor suppressor gene, wild type
  • PTEN tumor suppressor gene
  • Plasmid
  • 3 types of cationic liposomes

At Saisei, our cancer therapy combines local cancer tissue destruction with immunotherapy for a targeted, synergistic approach that minimizes side effects. We customize treatments based on cancer location and individual patient conditions, tailoring our approach to each unique case. Our methods are chosen for their specific benefits, aiming to balance effectiveness with minimal side effects to prioritize patient well-being and achieve the best possible health outcomes.

SAISEI Treatments

P53/PTEN Gene Therapy

Gene therapy for cancer is a cutting-edge treatment that targets the root cause of cancer development. Gene therapy is a therapeutic method that reduces genetic abnormalities that cause cancer.

GcMAF Treatment

GcMAF is a highly effective macrophage activating therapy, used to stimulate the immune system and activate macrophages so that they can destroy cancer cells and other abnormal cells in the body.

Dietary MAF

Oral MAF therapy is employed to enhance the immune system and activate macrophages to assist the body in overcoming disease, thereby supporting and protecting the organism.

TTF Treatment

Tumor Treating Fields (TTF) therapy is a type of electromagnetic field therapy using low-intensity electrical fields to suppress cancer cell division and proliferation. This treatment has been modernized to enhance its effectiveness.

HIFU Treatment

HIFU is a cutting-edge treatment that results in necrosis of cancer tissue after applying high-intensity focused ultrasound (HIFU) energy to a focused area with the action of thermal energy and cavitation.

PDT/SDT Treatment

Photodynamic therapy (PDT) and Sonodynamic therapy (SDT) are cutting-edge treatments which involve the use of non-toxic, light-sensitive and ultrasound-sensitive drugs. These treatments specifically target malignant and other diseased cells.

Safety of our Treatments

Our clinic employs cutting-edge therapies grounded in scientific discoveries and clinical research. We partner with several universities in Japan, as well as institutions and clinics abroad. Some of our treatments are exclusively patented by our company. Our primary focus is always to our patients, ensuring that our innovative approaches provide healing and support with minimal side effects. Our guiding principle is FIRST DO NO HARM, emphasizing our commitment to prioritizing the safety of treatments from the outset.

Patients Case Reports (Cancer)

60-year-old male, prostate cancer, Gleason score 8 (range 2 to 10)
・Feb 2011, initial diagnosis
・Feb 2011, radical prostatectomy, lymph node (-)
・No hormonal therapy
・PSA after surgery was increasing
・Oct 2011-Dec 2011, radiation, 60 Gy dose
・May 2012-Apr 2013, autologous serum GcMAF 72 times, IM (1500 ng/0.5 ml), high-dose IV vitamin C 60 g, 72 times
・Regional Hyperthermia, 21 times (Thermotron RF8)
・Feb 2013, MRI shows no metastatic tumors
・2014, normal PSA 0.058 ng/ml, no recurrence
60-year-old male with prostate cancer, Gleason score 8 diagnosed in February 2011.
He received radical prostatectomy without hormonal therapy, but after the surgery his PSA was increasing again.
He received radiation therapy, 60 Gray to his pelvic region.
In May 2012, he presented at Saisei Mirai Clinics. He received 72 times 0.5 ml high-dose GcMAF (1500 ng/0.5 ml)
high dose IV vitamin C 60 g and 21 times regional hyperthermia using Thermotron RF8.
In February 2013, MRI showed no metastatic tumors. The latest PSA level in 2014 was within the normal range, 0.058 ng/ml with no recurrence!

High Dose GcMAF (1500 ng, 0.5 ml) was administered once a week (total 24 times) together with
weekly high-dose intravenous vitamin C (total 39 times). Local Hyperthermia (Thermotron RF8)
was added once a week (total 19 times).
The patient had a complete response. The primary tumor and  multiple bone metastases have all disappeared according to the bone scintigram (bone scan/bone scintigraphy) and MRI.

72-year-old female patient first had surgery to remove the tumor in the colon and the ovary was also removed. Then she took high-dose
GcMAF (1500 ng, 0.5 ml) treatment once a week (total 48 times) and high-dose intravenous vitamin C once or twice a week
(total 66 times). During this period of time, she took targeted radiation therapy (Novalis Tx Radiosurgery) to the liver tumor
at a dose of 55 Gy.
After one year of treatment, PET CT scan showed no recurrence of the tumor. She is still in complete remission!

62-year-old female patient was diagnosed with stage 4B uterine cancer and lymph node metastasis after initial surgery in February 2011. Pathological diagnosis was Serous Adenocarcinoma, a rare and invasive cancer.
Prior treatment was 2 times chemotherapy in March 2011 with Carboplatin and Paclitaxel. After 2 times chemotherapy,
Pet CT scan showed recurrence in the left iliac artery and lymph nodes, and tumor markers were elevated. Patient then had second surgery of lymph nodes metastasis in the pelvis and left inguinal region and in addition prophylactic surgery.
In July 2011 patient had more chemotherapy with Cisplatin (CDDP) and radiation therapy, but new recurrence was found in the lymph node near the abdominal aorta which was followed by a fourth operation in November 2011,
and at the same time radiation therapy near the abdominal aorta.  
Patient presented at Saisei Mirai Clinics in Osaka in December 2011 after extensive prior treatment.
Chemotherapy had been discontinued due to the weakening condition of the patient from the side effects.
Immunotherapy was started at our clinic from December 2011, initially in combination with Regional Hyperthermia, oral Maitake MD-fraction 400 mg/day, and Low Dose Naltrexone (LDN). Maitake MD-fraction and LDN were continued long-term. Coley Vaccine therapy (Coley's Toxins) was started in January 2012 and high-dose GcMAF (1500 ng/0.5 ml) from February 2012.
Intravenous Coley Vaccine, total 110 times, starting at 5 times 1st week, then 2 times 2nd week, followed by 5 times.
3rd week, and so on, finishing with 1 time per week at the end. High-dose GcMAF (total 48 times), once per week, over
period of 1 year.
By 2013 the patient achieved complete remission. No tumor was visible in the CT scan and the tumor marker was at the bottom end of the normal range!



error: Content is protected !!